Takeda Pharmaceutical Company Limited (TAK) is expected to report earnings on Thursday, October 29, 2026, after the close. Consensus EPS estimate is $0.14.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | FY2026 Q2 | $0.17 | $0.23 | +33.2% | $7.66B |
| 2025-06-25 | FY2025 Q1 | $0.47 | $0.52 | +10.6% | $7.35B |
| 2024-06-30 | FY2024 Q2 | $0.37 | $0.20 | -45.1% | $8.05B |
| 2023-09-30 | FY2023 Q3 | $0.10 | $-0.10 | -207.1% | $6.97B |
| 2023-06-30 | FY2023 Q2 | $0.14 | $0.20 | +44.5% | $7.54B |
| 2023-03-31 | FY2023 Q1 | $0.05 | $0.08 | +49.7% | $7.07B |
| 2022-12-31 | FY2022 Q4 | $0.28 | $0.46 | +62.1% | $8.37B |
| 2022-06-30 | FY2022 Q2 | $0.24 | $0.56 | +135.8% | $7.28B |
TAK has beaten consensus EPS in 6 of its last 8 reported quarters.
See TAK on the live calendar →